AMENDMENT NO. 1 TO DEPOSIT AGREEMENT BETWEEN ABLYNX NV, JPMORGAN CHASE BANK, N.A. AS DEPOSITARY AND HOLDERS OF AMERICAN DEPOSITARY RECEIPTS WORLDWIDE SECURITIES SERVICES jpmorgan.comDeposit Agreement • October 2nd, 2017 • Ablynx NV • Biological products, (no disgnostic substances) • New York
Contract Type FiledOctober 2nd, 2017 Company Industry JurisdictionAMENDMENT NO. 1, dated as of , 2017 (the “Amendment”), to the Deposit Agreement dated as of September 5, 2014 (the “Deposit Agreement”), among Ablynx NV, incorporated under the laws of Belgium (the “Company”), JPMorgan Chase Bank, N.A., as depositary (the “Depositary”), and all holders from time to time of American depositary receipts (“ADRs”) issued thereunder.
RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT by and between MERCK SHARP & DOHME CORP. and ABLYNX N.V.Research Collaboration and Exclusive License Agreement • October 20th, 2017 • Ablynx NV • Biological products, (no disgnostic substances) • New York
Contract Type FiledOctober 20th, 2017 Company Industry JurisdictionTHIS RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT (this “Agreement”), effective as of January 31, 2014 (the “Effective Date”), is made by and between MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of New Jersey (“Merck”) and ABLYNX N.V., a limited liability company organized and existing under the laws of Belgium (“Ablynx”) registered with the legal entities register under number BE 0475295446 (district of Ghent) and whose registered office is situated at Technologiepark 21, 9052 Zwijnaarde, Belgium.
AMENDMENTLicense Agreement • October 20th, 2017 • Ablynx NV • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledOctober 20th, 2017 Company Industry JurisdictionThis amendment (”Amendment”), made on February 27, 2015, is an amendment to the license agreement with an effective date of May 20, 2010 (“Agreement”) entered into by and between Research Corporation Technologies, Inc., a Delaware nonprofit corporation with offices at 5210 E. Williams Circle, Suite 240, Tucson, Arizona 85711-4410 (“RCT”) and Ablynx N.V., a limited liability company organized under the laws of Belgium, registered with the legal entities register under number BE 475295446 (district of Ghent), whose registered office is situated at Technologiepark 21, 9052 Zwijnaarde, Belgium (hereinafter “Ablynx”).
ContractLicense Agreement • October 20th, 2017 • Ablynx NV • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledOctober 20th, 2017 Company Industry JurisdictionCONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[...***...]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
COLLABORATION AND LICENSE AGREEMENT between ABLYNX N.V. and SANOFICollaboration and License Agreement • October 13th, 2017 • Ablynx NV • Biological products, (no disgnostic substances) • New York
Contract Type FiledOctober 13th, 2017 Company Industry JurisdictionThis Collaboration and License Agreement (this “Agreement”) is entered into as of July 19, 2017 (the “Effective Date”), by and between Ablynx N.V., a company incorporated under the laws of Belgium having an address at Technologiepark 21, 9052 Zwijnaarde, Belgium (“Ablynx”), and Sanofi, a société anonyme duly organized and existing under the laws of France having an address at 54, rue de la Boétie, 75017 Paris, France (“Sanofi”). Ablynx and Sanofi may sometimes individually be referred to hereafter as a “Party” or, collectively, as the “Parties”.
EXCLUSIVE LICENSE AGREEMENT between ABLYNX NV and ABBVIE S.À.R.L. Dated as of September 20, 2013Exclusive License Agreement • October 2nd, 2017 • Ablynx NV • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledOctober 2nd, 2017 Company Industry JurisdictionThis Exclusive License Agreement (the “Agreement”) is made and entered into effective as of September 20, 2013 (the “Effective Date”) by and between Ablynx NV, a company organized under the laws of Belgium, having its principal place of business at Technologiepark 21, B-9052 Ghent—Zwijnaarde, Belgium (“Ablynx”), and AbbVie S.à.r.l., a corporation organized under the laws of Luxembourg and having a principal place of business at 26 Boulevard Royal; L-2449 Luxembourg (“AbbVie”). Ablynx and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENTCollaboration and Exclusive License Agreement • October 17th, 2017 • Ablynx NV • Biological products, (no disgnostic substances)
Contract Type FiledOctober 17th, 2017 Company IndustryThis amendment (”Amendment”), executed on July 20, 2015, is an amendment to the RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT with an effective date of January 31, 2014 (“Agreement”) entered into by and between MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of New Jersey (“Merck”) and ABLYNX N.V., a limited liability company organized and existing under the laws of Belgium (“Ablynx”) registered with the legal entities register under number BE 0475295446 (district of Ghent) and whose registered office is situated at Technologiepark 21, 9052 Zwijnaarde, Belgium.
EXCLUSIVE LICENSE AGREEMENT between ABLYNX NV and ABBVIE S.À.R.L. Dated as of September 20, 2013Exclusive License Agreement • August 10th, 2017 • Ablynx NV • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledAugust 10th, 2017 Company Industry JurisdictionThis Exclusive License Agreement (the “Agreement”) is made and entered into effective as of September 20, 2013 (the “Effective Date”) by and between Ablynx NV, a company organized under the laws of Belgium, having its principal place of business at Technologiepark 21, B-9052 Ghent—Zwijnaarde, Belgium (“Ablynx”), and AbbVie S.à.r.l., […***…] (“AbbVie”). Ablynx and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ABLYNX NV (a public limited liability company (“naamloze vennootschap”) organized and existing under the laws of the Kingdom of Belgium) Ordinary Shares and American Depositary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • October 17th, 2017 • Ablynx NV • Biological products, (no disgnostic substances) • New York
Contract Type FiledOctober 17th, 2017 Company Industry Jurisdiction
SERVICE AGREEMENT REGARDING BUSINESS-SUPPORT CENTRE “BIO-ACCELERATOR”Service Agreement • October 2nd, 2017 • Ablynx NV • Biological products, (no disgnostic substances)
Contract Type FiledOctober 2nd, 2017 Company IndustryOn 10 October 2008, the Parties entered into a framework agreement and prepared an accompanying memorandum on commitments in order to make agreements on the conclusion of a service agreement with respect to the Services and Business-Support Centre Bio-Accelerator in 9052 Zwijnaarde, Technologiepark 21 (hereinafter jointly referred to as the “Framework Agreement”).